摘要:
A phase difference plate includes a phase difference plate P1 and a phase difference plate P2. An in-plane slow axis of the phase difference plate P1 is orthogonal to an in-plane slow axis of the phase difference plate P2. The phase difference plate P2 includes a layer of a liquid crystal material oriented in an in-plane direction. An in-plane retardation ReP2(λ) at a wavelength A nm of the phase difference plate P2 satisfies the following formulae (e1) and (e2): {Re2 (400)−Re2(550)}/{Re2(550)−Re2(700)} 1.13 (e2). An in-plane retardation ReP1(λ) of the phase difference plate P1 at a wavelength λ nm and the in-plane retardation ReP2(λ) of the phase difference plate P2 at the wavelength λ nm satisfy the following formulae (e4) and (e5): ReP1(550)>ReP2(550) (e4), and ReP1(400)/ReP1(700)
摘要:
A borole compound is represented by Formula 1: X11—(R11)b11. X11, R11, and b11 are as defined herein. An organic light-emitting device includes the borole compound. The organic light-emitting device includes a first electrode, a second electrode, and an organic layer between the first electrode and the second electrode, the organic layer including an emission layer. The organic layer includes the borole compound.
摘要:
The present invention provides a novel benzene derivative or thiophene derivative useful as a VAP-1 inhibitor, or a medicament for the prophylaxis or treatment of a VAP-1 associated disease and the like, namely, a compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a pharmaceutically acceptable salt thereof.
摘要:
Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
摘要:
Potent low molecular weight, highly selective, competitive non-peptidic serine protease inhibitors and their use in treating serine protease-associated diseases are disclosed.
摘要:
Provided herein are non-peptide GLP-1 receptor modulator compounds, for example, of Formula I, pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of a metabolic disorder.
摘要:
The present invention provides a novel benzene derivative or thiophene derivative useful as a VAP-1 inhibitor, or a medicament for the prophylaxis or treatment of a VAP-1 associated disease and the like, namely, a compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a pharmaceutically acceptable salt thereof.
摘要:
The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
摘要:
To provide a catalyst for synthesis reaction which can achieve good yield in the Sonogashira reaction and also can be recovered after the reaction, and a method for synthesizing a compound in which the catalyst for synthesis reaction is used, a perovskite-type composite oxide containing palladium is used as the catalyst for synthesis reaction in the Sonogashira reaction represented by the following reaction scheme (1): R1—X+HC≡CR2→R1C≡CR2 (1)
摘要翻译:为了提供合成反应的催化剂,其能够在Sonogashira反应中获得良好的产率,并且也可以在反应后回收,以及合成其中使用合成反应的催化剂的化合物的方法,含有钯的钙钛矿型复合氧化物 用作由以下反应方案(1)表示的Sonogashira反应中的合成反应的催化剂:<?in-line-formula description =“In-line formula”end =“lead”?> R&lt; 1& / SUB + -X +HC≡CR2 - > R 1C≡CR2(1)<β在线公式描述 =“内联公式”end =“tail”?>
摘要:
A decarboxylation process for substituting cyano radicals for silver carboxylate radicals which comprises reacting the silver salts of carboxylic acids with silver cyanide under decarboxylation conditions of at least 320.degree.C.